STOCK TITAN
  1. Home
  2. Sec-filings
  3. MIRM
  4. [Form 4] Mirum Pharmaceuticals, Inc. Insider Trading Activity

Mirum Pharmaceuticals (MIRM) director receives RSUs and options grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Mirum Pharmaceuticals director Saira Ramasastry reported new equity awards. She received 1,980 restricted stock units and stock options for 3,772 shares of common stock with an exercise price of 101 per share. Both awards vest on the first anniversary of the grant date, or earlier if fully vested by Mirum’s 2027 annual stockholder meeting. The options expire on June 14, 2036. These are compensation-related grants rather than open-market purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Ramasastry Saira
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 3,772 $0.00 --
Grant/Award Restricted Stock Units 1,980 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 3,772 shares (Direct, null); Restricted Stock Units — 1,980 shares (Direct, null)
Footnotes (1)
  1. The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
Restricted stock units granted 1,980 units Award to director Saira Ramasastry on June 15, 2026
Stock options granted 3,772 options Award to director Saira Ramasastry on June 15, 2026
Option exercise price 101 per share Stock option (right to buy) for Mirum common stock
Option expiration date June 14, 2036 Expiration for 3,772 stock options granted
RSU underlying shares 1,980 shares Each restricted stock unit equals one common share upon vesting
Option underlying shares 3,772 shares Underlying Mirum common stock for granted options
Restricted Stock Units financial
"security_title: "Restricted Stock Units""
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
contingent right financial
"represents a contingent right to receive one share of the Issuer's common stock"
vest financial
"will vest on the first anniversary of the grant date"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ramasastry Saira
(Last)(First)(Middle)
C/O MIRUM PHARMACEUTICALS, INC.
989 E HILLSDALE BLVD., SUITE 300
(Street)
FOSTER CITY CALIFORNIA 94404
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$10106/15/2026A3,772 (1)06/14/2036Common Stock3,772$03,772D
Restricted Stock Units(2)06/15/2026A1,980 (2) (2)Common Stock1,980$01,980D
Explanation of Responses:
1. The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
/s/ Doug Sheehy, Attorney-in-Fact06/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Mirum Pharmaceuticals (MIRM) report for Saira Ramasastry?

Mirum Pharmaceuticals reported that director Saira Ramasastry received equity compensation grants. She was awarded 1,980 restricted stock units and options for 3,772 shares of common stock, all reported as acquisitions rather than open-market purchases or sales.

How many restricted stock units did Saira Ramasastry receive from Mirum Pharmaceuticals (MIRM)?

She received 1,980 restricted stock units. Each unit represents a contingent right to receive one share of Mirum’s common stock, subject to vesting conditions tied to the first anniversary of the grant and the 2027 annual stockholder meeting.

What stock options were granted to Saira Ramasastry by Mirum Pharmaceuticals (MIRM)?

She was granted options covering 3,772 shares of Mirum common stock. These options have an exercise price of 101 per share, were awarded as compensation, and expire on June 14, 2036, subject to vesting requirements.

When do Saira Ramasastry’s Mirum Pharmaceuticals (MIRM) equity awards vest?

Both the restricted stock units and stock options vest on the first anniversary of the grant date. In any case, they will be fully vested no later than the date of Mirum’s 2027 annual stockholder meeting, according to the footnotes.

Are Saira Ramasastry’s Mirum Pharmaceuticals (MIRM) Form 4 transactions open-market trades?

No, the transactions are equity compensation awards. The Form 4 shows grants of restricted stock units and stock options coded as awards, not open-market buys or sells, so they reflect compensation rather than trading activity.